Sebastian Aguiar: “The Geroscience Revolution.”

Sebastian Aguiar, geroscientist and Venture Fellow at Apollo Ventures, delivers the Lord Florey Lecture at Lincoln College, Oxford in November 2018. He was a Clarendon Scholar at Lincoln College, Oxford for his DPhil (PhD) on the biochemistry of aging. Aguiar presents topics such as the Silver Tsunami, promising industry developments, and exciting examples of healthspan…

What’s new in media and industry: Who’s who in longevity, and more

Here’s our handpicked selection of the best interviews, blog posts, popular articles, and breaking biotech news of the last two weeks: Want a systematic overview of every organization chipping away at human aging right now? Then you’ll love this nearly 800-page report from the Biogerontology Research Foundation. Put it in your queue for bedtime reading….

Glucosamine: The new metformin? | Interview with Dr. Michael Ristow (part ii)

Last week when we heard from Dr. Ristow, he turned the outdated notion of the “free radical theory of aging” on its head, and demonstrated that antioxidants like vitamin A and vitamin C aren’t all they’re cracked up to be. But if those supplements can’t help us, what can? Perhaps, says Ristow, the answer can…

What’s new in media and industry: Huge piles of money, and more

Here’s our handpicked selection of the best blog posts, popular articles, and breaking biotech news of the last two weeks: Longevity enthusiasts don’t need to feel left out of the mainstream funding frenzy anymore–Y Combinator has put a $1 million bounty on the head of aging, an attractively large figure for up-and-coming startups. Want to…

This chip can pluck the bad apples out of your blood

Many years from now, you’re reclining in one of the many gray-blue armchairs that line the walls of a clinic. Your arm is propped up on a collapsible plastic armrest, and two thin tubes lead from your wrist to the slender white machine next to you, one tube delivering your blood to the machine’s mysterious…

James Peyer: Where are stem cell therapies headed?

Someday soon we may be able to replace tissues or entire organs with those grown from a patients’ own stem cells… but just how soon? What challenges do stem cell therapies face on the path of development, as they progress from the lab to the commercial world? James Peyer, investor and former stem cell biologist, answers below…

Will this protein help speed up clinical trials?

Biomarkers are a big deal in the clinical world: if as a doctor you’re able to take one simple measurement that allows you to look into a patient’s future, you’ve potentially elevated your practice of medicine from imprecise art to exact science. The better the biomarkers in your arsenal, the more information you have to…

James Peyer: Why primary indications matter

“Aging” isn’t a disease as recognized by the FDA–not yet anyway. But then how will the companies trialing anti-aging drugs ever get regulatory approval? It’s simple: just choose a “primary indication” to test your drug with. Of course, that choice itself is rather difficult when you’re considering a geroprotector. Here’s how investors think about it…

James Peyer: Navigating the “Biotech Valley of Death”

Ever hear about an exciting discovery in the biomedical world, then later wonder why it seemingly dropped off the face of the Earth? In fact, it’s par for the course for potential therapeutics to fail before they ever get off the ground, guided unwittingly by their enthusiastic champions straight into a boneyard strewn with the…

James Peyer: “The 21st century will be defined by our struggle against the diseases of aging.”

“At what age would you like to get Alzheimer’s?” This was the question posed by venture capitalist, former stem cell biologist and Geroscience co-founder James Peyer at TEDxStuttgart last week. Peyer became a devotee and champion of the anti-aging movement early in his life, and over his career he’s watched the field mature from a collection…

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD